BSE · 543309
Adeshwar Meditex Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹84 Cr with net profit ₹2 Cr — a 2.46% net margin, versus 2.51% the period before.
Shareholding
As of 2026-03-31
- Promoter57.68%
- Public42.33%
192 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.68× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #49 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,522 Cr | 242.76 | 13.56 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,157 Cr | 315.71 | 10.06 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,929 Cr | 270.67 | 7.27 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,540 Cr | 188.89 | 9.38 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,437 Cr | 301.12 | 9.27 | 8.48% | 8.36% |
| Global Health Limited | ₹38,558 Cr | 267.56 | 9.73 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,827 Cr | 750.38 | 14.16 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,529 Cr | 239.29 | 12.57 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹16,980 Cr | 256.15 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,558 Cr | 392.64 | 7.68 | 6.58% | 6.4% |
| Adeshwar Meditex Limited(this company) | ₹24 Cr | 19.24 | 0.64 | 3.3% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashAdeshwar Meditex Limited, with a market capitalization of Rs 25 Cr, reported revenue of Rs 83.97 Cr. The company's PE ratio is 19.32 and its EPS stands at 0.88. Promoter holding is 57.675%, with public shareholding at 42.325%.
Positives
- +The Return on Equity (ROE) is significantly high at 330.4%.
- +Net profit increased to Rs 2.0657 Cr in Mar 2025 from Rs 2.008 Cr in Mar 2024.
- +Debt-to-equity ratio is 0.37, indicating a modest level of debt.
- +Promoter holding of 57.675% as of Mar 2026 is above 50%.
Negatives
- −The profit margin is 0%, indicating no reported profit as a percentage of revenue.
- −The company's Return on Capital Employed (ROCE) is relatively low at 5.5154%.
- −Quarterly results have not been disclosed consistently; only one quarter (Mar 2021) is available in the provided data.
- −The promoter shareholding decreased from 57.5503% in Sep 2024 to 42.6523% in Mar 2024, representing a significant decline.
- −No dividend yield is reported for the company.
Financial Performance
Adeshwar Meditex Limited’s revenue increased to Rs 83.97 Cr in Mar 2025, up from Rs 79.983 Cr in Mar 2024. Net profit also increased to Rs 2.0657 Cr in Mar 2025 from Rs 2.008 Cr in Mar 2024. The company's EPS remained at 1.43 in both Mar 2024 and Mar 2025.
Profitability & Returns
The company's Return on Capital Employed (ROCE) is 5.5154%. The Return on Equity (ROE) stands at 330.4%. The profit margin for Adeshwar Meditex Limited is 0%.
Balance Sheet
The company maintains a book value of Rs 26.53. Its debt-to-equity ratio is 0.37, indicating a relatively low level of debt compared to equity. No dividend yield is reported for the company.
Ownership & Pledges
As of Mar 2026, promoter holding in Adeshwar Meditex Limited was 57.675%. Public shareholding was 42.325%. There are no reported pledged promoter shares. The number of shareholders is 192.
Shareholding History
Promoter holding has seen fluctuations, declining from 57.5503% in Sep 2024 to 57.675% in Mar 2026. Prior to this, promoter holding increased from 42.6523% in Mar 2023 to 57.5503% in Sep 2024. Public shareholding has also varied over these periods.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.